Association Between Cancer and Sarcoidosis
Outcome Study of Sarcoidosis: a New Paraneoplastic Syndrome in Patient With Cancer
1 other identifier
observational
171
1 country
1
Brief Summary
The purpose of this study is to develop a clinical dataset of sarcoidosis patients with a diagnosis of cancer who are categorized by date of birth, sex, race/ethnicity, clinical information, laboratory and imaging information, time of sarcoidosis onset, cancer type and treatment, time of cancer diagnosis, stage and grade.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jul 2019
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 11, 2019
CompletedFirst Posted
Study publicly available on registry
February 18, 2019
CompletedStudy Start
First participant enrolled
July 4, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 16, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
September 16, 2021
CompletedMay 4, 2022
April 1, 2022
2.2 years
February 11, 2019
April 27, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Pathology Proven Sarcoidosis In Patients with Cancer
Number of Participants With Sarcoidosis Events as Assessed by Positive Granulomatous Reaction in the Biopsies of Lung, Mediastinal Lymph Nodes, or Other Organs After Cancer Diagnosis.
up to 10 years
Secondary Outcomes (2)
Cancer Cytogenetics and Sarcoidosis
up to 10 years
Treatment Requirement of Sarcoidosis
up to 10 years
Study Arms (1)
Patients with Sarcoidosis and Cancer
These group of patients have a diagnosis of Sarcoidosis and Cancer on the Pathological Report.
Eligibility Criteria
Patients with cancer who were seeking or receiving medical care at the University of Miami that satisfy the inclusion and exclusion criteria of study are eligible to participate.
You may qualify if:
- Clinical diagnosis of Sarcoidosis following cancer
- Granulomatous reaction must be proven by pathology
You may not qualify if:
- Aged younger than 18 years old.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Miami, Miller School of Medicine
Miami, Florida, 33136, United States
Related Publications (1)
Murthi M, Yoshioka K, Cho JH, Arias S, Danna E, Zaw M, Holt G, Tatsumi K, Kawasaki T, Mirsaeidi M. Presence of concurrent sarcoid-like granulomas indicates better survival in cancer patients: a retrospective cohort study. ERJ Open Res. 2020 Oct 26;6(4):00061-2020. doi: 10.1183/23120541.00061-2020. eCollection 2020 Oct.
PMID: 33263026DERIVED
Biospecimen
Pathological slides from patients, which contains Hematoxylin and Eosin ( H\&E) tissue stain fixation.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Mehdi Mirsaeidi, MD
University of Miami
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 11, 2019
First Posted
February 18, 2019
Study Start
July 4, 2019
Primary Completion
September 16, 2021
Study Completion
September 16, 2021
Last Updated
May 4, 2022
Record last verified: 2022-04
Data Sharing
- IPD Sharing
- Will not share